STATEMENT OF NEED
Based on recent estimates, kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 65,300 new cases are reported each year and more than 14,000 people die of the disease (ACS, 2018). Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. As a result of its often asymptomatic presentation, many patients present with advanced disease, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 67%, and drops to a dismal 12% for those with distant metastases (Siegel et al, 2018).
Medical oncologists, urologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with renal cell carcinoma.
Upon completion of this activity, participants should be able to:
- Describe the pathogenesis of RCC and the scientific foundation for targeted therapies
- Evaluate emerging data on the use of targeted therapies for advanced RCC
- Discuss relevant adverse events associated with targeted therapies for advanced RCC and evidence-based management strategies
Brian I. Rini, MD, FACP (Chairperson)
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Tian Zhang, MD
Assistant Professor of Medicine
Duke Cancer Institute
Daniel M. Geynisman, MD
Assistant Professor, Medical Oncology
Fox Chase Cancer Center
Eric Jonasch, MD
Professor, Department of Genitourinary Medical Oncology
The University of Texas
There is no fee to participate in or claim CME credit for this activity.
Please note that Penn State College of Medicine and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and i3health. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Relevant financial relationships exist between the following individuals and commercial interests:
Penn State College of Medicine staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Brian I. Rini, MD, FACP discloses that he has served as a consultant/advisor for and has received research grants from Bristol-Myers Squibb, Merck, Pfizer, and Roche.
Tian Zhang, MD discloses that she has served as a consultant/advisor for AstraZeneca, Bayer, Exelixis, Foundation Medicine, Genentech/Roche, Janssen, Pfizer, and Sanofi Aventis. She has received research grants from AbbVie/Stemcentrx, Janssen, Merrimack, Novartis, OmniSeq, Personal Genome Diagnostics, and Pfizer. She served on the speaker's bureau for Exelixis and Genentech/Roche. She also discloses that her spouse owns stock in and is affiliated through employment with Capio Biosciences.
Daniel M. Geynisman, MD discloses that he has served as a consultant/advisor for Exelixis and AstraZeneca.
Eric Jonasch, MD discloses that he has served as a consultant/advisor for Bristol-Myers Squibb, Eisai, Exelixis, Novartis, and Pfizer. He has presented on behalf of Exelixis and Novartis.
UNAPPROVED USE DISCLOSURE
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
This activity is supported by an independent educational grant from Exelixis.
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Penn State College of Medicine, i3 Health, or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.